Disparities in prostate cancer

Toward the Elimination of Cancer Disparities: Clinical and Public Health Perspectives

Volumn , Issue , 2009, Pages 179-202

  Brawley, Otis W ^a,b   Wallington, Sherrie Flynt ^c  

^a AMERICAN CANCER SOCIETY   (United States)

^b EMORY UNIVERSITY   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84856732764     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-89443-0_8     Document Type: Chapter

References (136)

1. Akaza, H., Miyanaga, N., Takashima, N., Naito, S., Hirao, Y., Tsukamoto, T. et al. Comparisons of percent equal producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean, and American residents. Jap J Clin Oncol. 2004; 34(2):86-89.
2. Albano, J.D., Ward, E., Jemal, A., Anderson, R., Cokkinides, V.E, Murray, T. et al. Cancer mortality in the United States by education level and race. J Natl Cancer Inst. 2007; 99(18):1384-1394.
3. American Cancer Society (2009). Chief medical officer Otis W. Brawley responds to prostate cancer studies. American Cancer Society. Retrieved March 25, 2008, from http://www. cancer.org/docroot/MED/content/MED-2-1-Chief-Medical- Officer-Otis-W-Brawley- Responds-to-Prostate-Studies.asp.
4. Amling, C.L., Kane, C.J., Riffenburgh, R.H., Ward, J.F., Roberts, J.L., Lance, R.S. et al. Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology. 2001; 58(5):723-728.
5. Amling, C.L., Riffenburg, R.H., Sun, L., Moul, J.W., Lance, R.S., Kusada, L. et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004; 22(3):439-445.
6. Andriole, G.L., Grubb, R.L., III, Buys, S.S., Chia, D., Church, T.R., Fouad, M.N., et al. Mortality results from a radomized prostate-cancer screening trial. New Engl J Med. 2009; 360(13). Retrieved March 26, 2009, from http://content.nejm.org/cgi/content/full/NEJMoa0810696
7. Austin, J.P., Convery, K. Age-race interaction in prostatic adenocarcinoma treated with external beam irradiation. Am J Clin Oncol. 1993; 16(2):140-145.
8. Austin, J.P., Aziz, H., Potters, L., Thelmo, W., Chen, P., Choi, K. et al. Diminished survival of young blacks with adenocarcinoma of the prostate. Am J Clin Oncol. 1990; 13(6):465-469.
9. Bangsi, D., Zhou, J., Sun, Y., Patel, N.P., Darga, L.L., Heilbrun, L.K. et al. Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men. Urol Oncol. 2006; 24(1):21-27.
10. Bach, P.B., Schrag, D., Brawley, O.W., Galaznik, A., Yakren, S., Begg, C.B. Survival of black and whites after a cancer diagnosis. J Am Med Assoc. 2002; 287(16):2106-2113.
11. Barry, M.J. Screening for prostate cancer - The controversy that refuses to die. New Engl J Med. 2009; 360(13). Retrieved March 26, 2009, from http://content. nejm.org/cgi/content/full/NEJMe0901166
12. Bennett, C.L., Ferreira, M.R., Davis, T.C., Kaplan, J., Weinberger, M., Kuzel, T. et al. Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer. J Clin Oncol. 1998; 16(9):3101-3104.
13. Bennett, C.L., Price, D.K., Kim, S., Liu, D., Jovanovic, B.D., Nathan, D. et al. Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J Clin Oncol. 2002; 20(17):3599-3604.
14. Ben-Shlomo, Y., Evans, S., Ibrahim, F., Patel, B., Anson, K., Chinegwundoh, F. et al. The risk of prostate cancer amongst black men in the United Kingdom: the PROCESS cohort study. Eur Urology. 2008; 53(1):99-105.
15. Brawley, O.W. Some perspective on black-white cancer statistics. CA Cancer J Clin. 2002; 52(6):322-325.
16. Brawley, O.W. Population categorization and cancer statistics. Cancer Metastasis Rev. 2003; 22(1):11-19.
17. Brawley, O.W., Ford, L.G., Thompson, I., Perlman, J.A., Kramer, B.S. 5-Alpha reductase inhibition and prostate cancer prevention. Cancer Epidemiol Biomarkers Prev. 1994; 3(2):177-182.
18. Brewster, D.H., Thomson, C.S., Hole, D.J., Black, R.J., Stroner, P.L., Gillis, C.R. Relation between socioeconomic status and tumor stage in patients with breast, colorectal, ovarian, and lung cancer: results from four national, population based studies. BMJ. 2001; 322(7290):830-831.
19. Boyle, P. Screening for prostate cancer: have you had your cholesterol measured? BJU Int. 2003; 92(3):191-199.
20. Brown, M.L., Potosky, A.L. The presidential effect: the public health response to media coverage about Ronald Reagan's colon cancer episode. Pub Op Quarterly. 1990; 54(3):317-329.
21. Collin, S.M., Martin, R.M., Metcalfe, C., Gunnell, D., Albertsen, P.C., Neal, D. et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol. 2008; 9(5):445-452.
22. Connell, P.P., Ignacio, L., Haraf, D., Awan, A.M., Halpern, H., Abdalla, I. et al. Equivalent racial outcome after conformal radiotherapy for prostate cancer: a single departmental experience. J Clin Oncol. 2001; 19(1):54-61.
23. Cooperberg, M.R., Lubeck, D.P., Meng, M.V., Mehta, S.S., Carroll, P.R. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2006; 22(11):2141-2149.
24. de Koning, H.J., Auvinen, A., Berenguer-Sanchez, A., Calais da Silva, F, Ciatto, S., Denis, L. et al. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary Cancer trial. Int J Cancer. 2002; 97(2):237-244.
25. Du, X.L., Fang, S., Coker, A.L., Sanderson, M., Aragaki, C., Cormier, J.N. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort. Cancer. 2006; 106(6):1276-1285.
26. Duffy, S.W., Nagtegaal, I.D., Wallis, M., Cafferty, F.H., Houssami, Warwick, J. et al. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. Am J Epid. 2008; 168(1):98-104.
27. Edwards, B.K., Brown, M.L., Wingo, P.A., Howe, H.L., Ward, E., Ries, L.A. et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005; 97(19):1407-1427.
28. Etzioni, R., Penson, D.F., Legler, J.M., di Tommaso, D., Boer, R., Gann, P.H. et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002; 94(13):981-990.
29. Fiscella, K., Williams, D.R. Health disparities based on socioeconomic inequities: implications for urban health care. Acad Med. 2004; 79(12):1139-1147.
30. Fowler, J.E., Bigler, S.A. Renfroe, D.L., Dabagia, M.D. Prostate specific antigen in black and white men after hormonal therapies for prostate cancer. J Urol. 1997; 158(1): 150-154.
31. Fowler, J.E., Jr., Terrell, F.L.,Renfroe,D.L. Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. J Urol. 1996; 156(5):1714-1718.
32. Freedland, S.J., Jalkut, M., Dorey, F., Sutter, M.E., Aronson, W.J. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center. Urology. 2000; 56(1):87-91.
33. Gilligan, T., Wang, P.S., Levin, R., Kantoff, P.W., Avorn, J. Racial differences in screening for prostate cancer in the elderly. Arch Int Med. 2004; 164:1858-1864.
34. Giovannucci, E. Vitamin D and cancer incidence in the Harvard cohorts. Ann Epid. 2009; 19(2):87-88.
35. Giovannucci, E., Liu, Y., Platz, E.A., Stampfer, M.J., Willet, W.C. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer. 2007; 121(7):1571-1578.
36. Glover, F.E., Jr., Coffey, D.S., Douglas, L.L., Cadogan, M., Russell, H., Tulloch, T. et al. The epidemiology of prostate cancer in Jamaica. J Urol. 1998; 159(6):1984-1986.
37. Godley, P.A., Schenck, A.P., Amamoo, M.A., Schoenbach, V.J., Peacock, S., Manning, M. et al. Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst. 2003; 95(22):1702-1710.
38. Gordon, N.H. Association of education and income with estrogen receptor status in primary breast cancer. Am J Epid. 1995; 142(8):796-803.
39. Greenlee, R.T., Murray, T., Bolden, S., Wing, P.A., Cancer Statistics, 50: 7-33, 2000
40. Gross, C.P., Smith, B.D., Wolf, E., Andersen, M. Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002? Cancer. 2008; 112(4):900-908.
41. Haenszel, W. Studies of migrant populations. Am J Pub Health. 1985; 75(3):225-226.
42. Haenszel, W., Kurihara, M. Studies of Japanese migrants: mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst. 1968; 40(1):43-68.
43. Halpern, M.T., Ward, E.M., Pavluck, A.L., Schrag, N.M., Bian, J., Chen, A.Y. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol. 2008; 9(3):222-231.
44. Harlan, L., Brawley, O., Pommerenke, F.,Wali, P.,Kramer, B. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol. 1995; 13(1):93-100.
45. Harlan, L.C., Coates, R.J., Block, G.,Greenberg, R.S., Ershow, A., Forman,M. et al. Estrogen receptor status and dietary intakes in breast cancer patients. Epid. 1993; 4(1):25-31.
46. Harlan, L.C., Potosky, A., Gilliland, F.D., Hoffman, R., Albertsen, P.C., Hamilton, A.S. et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst. 2001; 93(24):1864-1871.
47. Hart, K.B., Wood, D.P., Jr., Tekyi-Mensah, S., Porter, A.T., Pontes, J.E., Forman, J.D. The impact of race on biochemical disease-free survival in early-stage prostate cancer patients treatedwith surgery or radiation therapy. Int JRadOncol Biol Phys. 1999; 45(5):1235-1238.
48. Hernandez, W., Grenade, C., Santos, E.R., Bonilla, C., Ahaghotu, C., Kittles, R.A. IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African- Americans. Carcinogenesis. 2007; 28(10):2154-2159.
49. Ingles, S.A., Ross, R.K., Yu, M.C., Irvine, R.A., La, P.G., Haile, R.W. et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst. 1997; 89(2):166-170.
50. Irvine, R.A., Yu, M.C., Ross, R.K., Coetzee, G.A. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res. 1995; 55(9):1937-1940.
51. Iselin, C.E., Box, J.W., Vollmer, R.T., Layfield, L.J., Robertson, J.E., Paulson, D.F. Surgical control of clinically localized prostate carcinoma equivalent in African-American and white males. Cancer. 1998; 83(11):2353-2360.
52. Johnstone, P.A., Kane, C.J., Sun, L., Wu, H., Moul, J.W., McLeod, D.G. et al. Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research. Radiology. 2002; 225(2):420-426.
53. Kane, C.J., Lubeck, D.P., Knight, S.J., Spitalny, M., Downs, T.M., Grossfeld, G.D. et al. Impact of patient educational level on treatment for patients with prostate cancer: data from CaPSURE. Urology. 2003; 62(6):1035-1039.
54. Kidd, L.C., Paltoo, D.N., Wang, S., Chen, W., Akereyeni, F., Issacs, W. et al. Sequence variation within the 5' regulatory regions of the vitamin D binding protein and receptor genes and prostate cancer risk. Prostate. 2005;64(3):272-282.
55. Kim, J.A., Kuban, D.A, el-Mahdi, A.M., Schellhammer, P.F. Carcinoma of the prostate: race as a prognostic indicator in definitive radiation therapy. Radiology. 1995; 194(2):545-549.
56. Kittles, R.A., Young, D., Weinrich, S., Hudson, J., Argyropoulos, G., Ukoli, F. et al. Extent of linkage disequilibriumbetween the androgen receptor gene CAG and GGC repeats in human populations: implications for prostate cancer risk. Hum Genet. 2001; 109(3):253-261.
57. Klabunde, C.N., Potosky, A.L., Harlan, L.C., Kramer, B.S. Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care. 1998; 36(9):1337-1348.
58. Klein, E.A. Selenium and vitamin E cancer prevention trial. Ann NY Acad Sci. 2004; 1031:234-241.
59. Klein, E.A., Silverman, R. Inflammation, infection, and prostate cancer. Curr Op Urol. 2008; 18(3):315-319.
60. Klein, E.A., Casey, G., Silverman, R. Genetic susceptibility and oxidative stress in prostate cancer: integrated model with implications for prevention. Urology 2006; 68(6):1145-1151.
61. Kramer, B.S., Brown, M.L., Prorok, P.C., Potosky, A.L., Gohagen, J.K. Prostate cancer screening: what we know and what we need to know. Ann Int Med. 1993; 119(9):914-923.
62. Kripalani, S., Sharma, J., Justice, E., Justice, J., Spiker, C., Laufman, L.E. et al. Low-literacy interventions to promote discussion of prostate cancer: a randomized controlled trial. Am J Prev Med. 2007; 33(2):83-90.
63. Kumar, R.J., Baha Barqawi, A.B., Crawford, E.D. Epidemiology of prostate cancer. Business Briefing: US Oncology Review 2004: 42-45.
64. Liu, L., Cozen, W., Bernstein, L., Ross, R.K., Deapen, D. Changing relationship between socioeconomic status and prostate cancer incidence. J Natl Cancer Inst. 2001; 93(9):705-709.
65. Litman, H.J., Bhasin, S., Link, C.L., Araujo, A.B., McKinlay, J.B. Serum androgen levels in black, Hispanic, and white men. J Clin Endocrin Metab. 2006; 91(11):4326-4334.
66. Lu-Yao, G., Albertsen, P.C., Stanford, J.L., Stukel, T.A., Walker-Corkery, E.S., Barry, M.J. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ. 2002; 325(7367):740.
67. Lu-Yao, G., Moore, D.F., Oleynick, J., DiPaola, R.S., Yao, S.L. Use of hormonal therapy in men with metastatic prostate cancer. J Urol. 2006; 176(2):526-531.
68. Mariotto, A.B., Etzioni, R., Krapcho, M., Feuer, E.J. Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer. 2007; 109(9):1877-1886.
69. McLeod, D.G., Schellhammer, P.F., Vogelzang, N.J., Soloway, M.S., Sharifi, R., Black, N.L. et al. Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group. Prostate. 1999; 40(4):218-224.
70. Miller, D.C., Gruber, S.B., Hollenbeck, B.K., Montie, J.E., Wei, J.T. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst. 2006; 98(16):1134-1141.
71. Morris, C.R., Snipes, K.P., Schlag, R., Wright, W.E. Sociodemographic factors associated with prostatectomy utilization and concordance with the physician data query for prostate cancer (United States). Cancer Causes Control. 1999; 10(6):503-511.
72. Moul, J., Douglas, T., McCarthy, W., McLeod, D. Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol. 1996; 155(5):1667-1672.
73. Nielsen, M.E., Han, M., Mangold, L., Humphreys, E., Walsh, P.C., Partin, A.W. et al. Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center. J Urol. 2006; 176(2): 515-519.
74. Oakley-Girvan, I., Kolonel, L.N., Gallagher, R.P., Wu, A.H., Felberg, A., Whittemore, A.S. Stage at diagnosis and survival in a multiethnic cohort of prostate cancer patients. Am J Pub Health. 2003; 93(10):1753-1759.
75. Odedina, F.T., Ogunbiyi, J.O., Ukoli, F.A. Roots of prostate cancer in African-American men. J Natl Med Assn. 2006; 98(4):539-543.
76. Pan, C.C., Lee, J.S., Chan, J.L., Sandler, H.M., Underwood, W., McLaughlin, P.W. The association between presentation PSA and race in two sequential time periods in prostate cancer patients seen at a university hospital and its community affiliates. Int J Rad Oncology, Biology, Physics. 2003; 57(5):1292-1296.
77. Panz, V.R., Joffe, B.I., Spitz, I., Lindenberg, T., Farkas, A., Haffejee, M. Tandem CAG repeats of the androgen receptor gene and prostate cancer risk in black and white men. Endocrine. 2001; 15(2):213-216.
78. Park, J., Chen, L., Ratnashinge, L., Sellers, T.A., Tanner, J.P., Lee, J.H. et al. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men. Cancer, Epidemiology, Biomarkers, and Prevention. 2006; 15(8):1473-1478.
79. Parkin, D.M., Whelan, S.L., Ferlay, J., Raymond, L., Young, J., eds. Cancer Incidence in Five Continents, Vol 7. Lyon (France), IARC Scientific Publication No. 143, IARC Press; 1997.
80. Peters, N., Armstrong, K. Racial differences in prostate cancer treatment outcomes. Cancer Nurs. 2005; 28(2):108-116.
81. Phillips, A.A., Jacobson, J.S., Magai, C., Consedine, N., Horowicz-Mehler, N.C., Neugut, A.I. Cancer incidence and mortality in the Caribbean. Cancer Invest. 2007; 25(6):476-483.
82. Platz, E.A., Rimm, E.B., Willett, W.C., Kantoff, P.W., Giovannucci, E. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst. 2000; 92(24):2009-2017.
83. Polednak, A.P. Stage at diagnosis of prostate cancer in Connecticut by poverty and race. Ethnicity and Disease. 1997; 7(3):215-220.
84. Potosky, A.L., Feuer, E.J., Levin, D.L. Impact of screening on incidence and mortality in the United States. Epidem Rev. 2001; 23(1):181-186.
85. Powell, I.J., Dey, J., Dudley, A., Pontes, J.E., Cher, M.L., Sakr, W. et al. Disease-free survival difference between African Americans and whites after radical prostatectomy for local prostate cancer: a multivariable analysis. Urol. 2002; 59: 907-912.
86. Powell, I.J., Land, S.J., Dey, J., Heilbrun, L.K., Hughes, M.R., Sakr, W. et al. The impact of CAG repeats in exon 1 of the androgen receptor on disease progression after prostatectomy. Cancer. 2005; 103(3):528-537.
87. Reed, A., Ankerst, D.P., Pollack, B.H., Thompson, I.M., Parekh, D.J. Current age and race adjusted prostate specific antigen threshold values delay diagnosis of high grade prostate cancer. J Urol. 2007; 178(5):1929-1932.
88. Ries L.A.G., Melbert, D., Krapcho, M., Stinchcomb, D.G., Howlader, N., Horner, M.J., Mariotto,A., Miller, B.A., Feuer, E.J.,Altekruse, S.F., Lewis, D.R.,Clegg, L., Eisner,M.P., Reichman, M., Edwards, B.K., (Eds). SEER Cancer Statistics Review, 1975-2005
89. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975- 2005, based on November 2007 SEER data submission, posted to the SEER web site, 2008.
90. Ries, L.A.G., Harkins, D., Krapcho, M., Mariotto, A., Miller, B.A., Feuer, E.J. et al. SEER cancer statistic review, 1975-2003.
91. Bethesda: National Cancer Institute, 2006 http://www. seercancer.gov/csr/1975-2002. Accessed August 4, 2008
92. Accessed August 4, 2008. Roach, M., III. Krall, J., Keller, J.W., Perez, C.A., Sause, W.T., Doggett, R.L. et al. The prognostic significance of race and survival from prostate cancer based on patients irradiated on Radiation Therapy Oncology Group protocols (1976-1985). Int J Rad Oncol Biol Phys. 1992; 24(3):441-449.
93. Robbins, A.S., Whittemore, A.S., Thom, D.H. Differences in socioeconomic status and survival among white and black men with prostate cancer. Am J Epidem. 2000; 151(4):409-416.
94. Robbins, A.S., Yin, D., Parikh-Patel, A. Differences in prognostic factors and survival among white men and black men with prostate cancer, California, 1995-2004. Am J Epidem. 2007; 166(1):71-78.
95. Rodriguez, C., McCullough, M.L., Mondul, A.M., Jacobs, E.J., Chao, A., Patel, A.V. et al. Meat consumption among blacks and white men and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidem Biomarkers Prev. 2006; 15(2):211-216.
96. Roetzheim, R.G., Pal, N., Tennant, C., Voti, L., Ayanian, J.Z., Schwabe, A. et al. Effects of health insurance and race on early detection of cancer. J Natl Cancer Inst. 1999; 91(16):1409-1415.
97. Rohrmann, S., Nelson, W.G., Rifai, N., Brown, T.R., Dobs, A., Kanarek, N. et al. Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin Endo Met. 2007; 92(7):2519-2525.
98. Ross, R.K. The role of molecular genetics in chemoprevention studies of prostate cancer. IARC Scientific Publications. 2001; 154:207-213.
99. Ross, L.E., Berkowitz, Z., Ekwueme, D.U. Use of the prostate-specific antigen test among U.S. men: findings from the 2005 National Health Interview Survey. Cancer, Epidemiology, Biomarkers, and Prevention. 2008; 17(3):636-644.
100. Ross, R.K., Pike, M.C., Coetzee, G.A., Reichardt, J.K., Yu, M.C., Feigelson, H. et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res. 1998; 58(20):4497-4504.
101. Sakr, W.A., Billis, A., Ekman, P., Wilt, T., Bostwick, D.G. Epidemiology of high-grade prostatic intraepithelial neoplasia. Scand J Urol Nephr. Supp, 2000; 205:11-18.
102. Sakr, W.A., Grignon, D.J., Crissman, J.D., Heilbrun, L.K., Cassin, B.J., Pontes, J.J. et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo. 1994; 8(3):439-443.
103. Salam, M.T., Ursin, G., Skinner, E.C., Dessissa, T., Reichardt, J.K. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. Urol Oncol. 2005; 23(4):246-253.
104. Sanchez-Chapado, M., Olmedilla, G., Cabeza, M., Donat, E., Ruiz, A. Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: an autopsy study. Prostate. 2003; 54(3):238-247.
105. Sarter, O., Zheng, Q., Eastham, J.A. Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer. Urol. 1999; 53(2):378-380.
106. Satia-Abouta, J., Patterson, R.E., Schiller, R.N., Kristal, A.R. Energy from fat is associated with obesity in U.S. men: results from the Prostate Cancer Prevention Trial. Prev Med. 2002; 34(5):493-501.
107. Schroder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L.J., Ciatto, S., Nelen, V., et al. Screening and prostate-cancer mortality in a randomized European study. New Engl J Med. 2009; 360(13) Retrieved March 26, 2009, from http://content.nejm.org/cgi/content/full/NEJMoa0810084.
108. Schumacher, F.R., Feigelson, H.S., Cox, D.G., Haiman, C.A., Albanes, D., Buring, J. et al. A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res. 2007; 67(7):2951-2956.
109. Schwartz, K.L., Crossley-May, H., Vigneau, F.D., Brown, K., Banerjee, M. Race, socioeconomic status and stage at diagnosis for five common malignancies. Cancer Causes Control. 2003; 14(8):761-766.
110. Shavers, V.L., Brown, M.L. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 94(5):334-357.
111. Shavers, V.L., Brown, M.L., Potosky, A.L., Klabunde, C.N., Davis, W.W., Moul, J.W. et al. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J General Int Med. 2004; 19(2): 146-155.
112. Shekarriz, B., Tiguert, R., Upadhyay, J., Gheiler, E., Powell, I.J., Pontes, J.E. et al. Impact of location and multifocality of positive surgical margins on disease-free survival following radical prostatectomy: a comparison between African-American and white men. Urol. 2000; 55(6):899-903.
113. Shibata, A., Ma, J., Whittemore, A.S. Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst. 1998; 90(16):1230-1231.
114. Shibata, A., Whittemore, A.S. Re: Prostate cancer incidence and mortality in the United States and the United Kingdom. (Letter). J Natl Cancer Inst. 2001; 93(14):1109-1110.
115. Soos, G., Tsakiris, I., Szanto, J., Turzo, C., Haas, P.G., Dezso, B. The prevalence of prostate carcinoma and its precursor in Hungary: an autopsy study. Eur Urol. 2005; 48(5):739-744.
116. Spangler, E., Zeigler-Johnson, C.M., Coomes, M., Malkowicz, S.B., Wein, A., Rebbeck, T.R. Association of obesity with tumor characteristics and treatment failure of prostate cancer in African-American and European American men. J Urol. 2007; 178(5):1939-1944.
117. Stangelberger, A., Waldert, M., Djavan, B. Prostate cancer in elderly men. Rev Urol. 2008; 10(2):111-119.
118. Steenland, K., Rodriguez, C., Mondul, A., Calle, E.E., Thun, M. Prostate cancer incidence and survival in relation to education (United States). Cancer Causes Control. 2004; 15(9):939-945.
119. Tannock, I.F., de Wit, R., Horti, J., Pluzanska, A., Chi, K.N. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, NEJM. 2004; 351(15):1502-1512.
120. Tarman, G.J., Kane, C.J., Moul, J.W., Thrasher, J.B., Foley, J.P., Wilhite, D. et al. Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system. Urol. 2000; 56(6):1016-1020.
121. Taylor, K.L., Davis, J.L., III., Turner, R.O., Johnson, L., Schwartz, M.D., Kerner, J.F. et al. Educating African American men about the prostate cancer screening dilemma: A randomized intervention. Cancer Epidem Biomarkers Prev. 2006; 15:2179-2188.
122. Telesca, D., Etzioni, R., Gulati, R. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics. 2007; 64(1):10-19.
123. Thompson, I.M., Ankerst, D.P., Chi, C., Goodman, P.J., Tangen, C.M., Lucia, M.S. et al. Assessing prostate cancer risk: results form the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006; 98(8):529-534.
124. Thompson, I.M., Basler, J.A., Leach, R., Troyer, D., Klein, E., Brawley, O. Challenges and opportunities to the design and implementation of chemoprevention trials for prostate cancer. Urol Oncol. 2003; 21(1):73-78.
125. Thompson, I.M., Goodman, P.J., Tangen, C.M., Lucia, M.S., Miller, G.J., Ford, L.G. et al. The influence of finasteride on the development of prostate cancer, NEJM. 2003; 349(3):215-224.
126. U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Task Force Recommendation Statement. Ann Int Med. 2008; 149 (3):185-191.
127. Vogt, T.M., Ziegler, R.G., Patterson, B.H., Graubard, B.I. Racial differences in serum selenium concentration: analysis of US population data from the Third National Health and Nutrition Examination Survey. Am J Epidem. 2007; 166(3):280-288.
128. Williams, D.R. Race, health, and health care. St. Louis Univ Law J. 2003; 48(1):13-35.
129. Williams, D.R. The health of men: Structured inequalities and opportunities. Am J Pub Health. 2003; 93(5):724-731.
130. Williams, D.R. The health of U.S. racial and ethnic populations. Journal of Gerontology. Series B. Psych Sci Soc Scie. 2005; 60(2):53-62.
131. Williams, D.R., Collins, C. U.S. socioeconomic and racial differences in health. Annual Review of Sociology. 1995; 21:349-386.
132. Williams, D.R., Jackson, P.B. Social sources of racial disparities in health. Health Affairs (Millwood). 2005; 24(2):325-334.
133. Wolf, M.S., Knight, S.J., Lyons, E.A., Durazo-Arvizu, R., Pickard, S.A., Arseven, A. et al. Literacy, race, and PSA level among low-income men newly diagnosed with prostate cancer. Urol. 2006; 68(1):89-93.
134. Wood, H.M., Reuther, A.M., Gilligan, T.D., Kupelian, P.A., Modlin, C.S., Jr., Klein, E.A. Rates of biochemical remission remain higher in black men compared to white men after radical prostatectomy despite similar trends in prostate specific antigen induced stage migration. Journal of Urology. 2007; 178(4 Pt 1):1271-1276.
135. Yao, S.L., Lu-Yao, G. Understanding and appreciating overdiagnosis in the PSA era. J Nat Cancer Inst. 2002; 94(13):958-960.
136. Young, C.D., Lewis, P., Weinberg, V., Lee, T.T., Coleman, C.W., Roach, M, III. The impact of race on freedom from prostate-specific antigen failure in prostate cancer patients treated with definite radiation therapy. Semin Urol Oncol. 2000; 18(2):121-126.